Intraoperative Ultrasound Staging for Colorectal Liver Metastases in the Era of Liver-Specific Magnetic Resonance Imaging: Is It Still Worthwhile?
Table 4
Univariate and multivariate analyses of factors predicting missing metastases at MRI.
Univariate analysis
Multivariate analysis
Missing CRLMs (n = 146)
No missing CRLMs (n = 575)
OR (CI 95%)
Age (years)
63 ± 10.6
64 ± 10.8
0.742
—
Sex male
105 (71.9)
348 (60.5)
0.011
n.s.
BMI ≥30 kg/m2
24 (16.4)
85 (14.8)
0.618
Chemotherapy regimen data
Preoperative chemotherapy
115 (78.8)
374 (65.0)
0.002
n.s
Oxaliplatin based
82 (56.2)
276 (48.0)
0.078
—
Irinotecan based
58 (39.7)
150 (26.1)
0.001
n.s
Oxaliplatin or irinoteca plus biologics
87 (59.6)
222 (38.6)
<0.001
n.s
Number of cycles
6 ± 7.50
4 ± 5.66
<0.001
—
Number of cycles >5
94 (64.4)
284 (49.4)
0.001
n.s
Preoperative imaging data
Number of CRLMs
4 ± 3.9
2 ± 4.2
<0.001
—
Number of CRLMs >3
97 (66.4)
261 (45.4)
<0.001
n.s
Diameter (mm)
20 ± 17.2
24 ± 23.0
0.103
—
Location
Subglissonian
25 (17.1)
3 (0.5)
<0.001
44.494 (11.785–167.977)
<0.001
Hepatic dome
60 (41)
10 (1.7)
<0.001
46.097 (20.911–101.617)
<0.001
Mucinous histology
42 (28.8)
14 (2.4)
<0.001
23.805 (11.173–50.719)
<0.001
Redo-resection
8 (5.5)
42 (7.3)
0.438
—
Hepatic steatosis
111 (76.0)
396 (68.9)
0.091
—
Mild
59 (40.4)
232 (40.3)
0.988
—
Moderate
42 (28.7)
117 (20.3)
0.037
n.s.
Severe
10 (6.8)
47 (8.1)
0.720
—
No fatty
35 (23.9)
179 (31.1)
0.112
—
Data are expressed as number (%) or median ± SD. BMI, body mass index; LM, liver metastasis; MRI, magnetic resonance imaging; IOUS, intraoperative ultrasonography. Bevacizumab or cetuximab or panitumumab.
